TY - JOUR
T1 - Gyrification abnormalities in presymptomatic c9orf72 expansion carriers
AU - Caverzasi, Eduardo
AU - Battistella, Giovanni
AU - Chu, Stephanie A.
AU - Rosen, Howie
AU - Zanto, Theodore P.
AU - Karydas, Anna
AU - Shwe, Wendy
AU - Coppola, Giovanni
AU - Geschwind, Daniel H.
AU - Rademakers, Rosa
AU - Miller, Bruce L.
AU - Gorno-Tempini, Maria Luisa
AU - Lee, Suzee E.
N1 - Funding Information:
This work was supported by the National Institutes of Health [SEL: R01 AG058233, K23AG039414; TPZ: F32AG030249,R01MH096861; MGT: R01NS050915, K24DC015544; GC: AG035610; RR: R35NS097261; BLM:P01AG019724, P50AG23501]. The John Douglas French Alzheimer's Foundation[GC]. State of California DHS04-35516[MGT]. Samples from the National Cell Repository for Alzheimer's Disease(NCRAD), which receives government support under a cooperative agreement grant(U24AG21886) awarded by the National Institute on Aging (NIA), were used in this study.
Funding Information:
Funding This work was supported by the National Institutes of health [seL: R01 aG058233, K23aG039414; TpZ: F32aG030249,R01Mh096861; MGT: R01Ns050915, K24Dc015544; Gc: aG035610; RR: R35Ns097261; BLM:p01aG019724, p50aG23501]. The John Douglas French alzheimer’s Foundation[Gc]. state of california Dhs04-35516[MGT]. samples from the National cell Repository for alzheimer’s Disease(NcRaD), which receives government support under a cooperative agreement grant(U24aG21886) awarded by the National Institute on aging (NIa), were used in this study.
Publisher Copyright:
© © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
PY - 2019/9/1
Y1 - 2019/9/1
N2 - Objective To investigate in-vivo cortical gyrification patterns measured by the local gyrification index (lGI) in presymptomatic c9orf72 expansion carriers compared with healthy controls, and investigate relationships between lGI and cortical thickness, an established morphometric measure of neurodegeneration. Methods We assessed cortical gyrification and thickness patterns in a cohort of 15 presymptomatic c9orf72 expansion carriers (age 43.7 ± 10.2 years, 9 females) compared with 67 (age 42.4 ± 12.4 years, 36 females) age and sex matched healthy controls using the dedicated Freesurfer pipeline. Results Compared with controls, presymptomatic carriers showed significantly lower lGI in left frontal and right parieto-occipital regions. Interestingly, those areas with abnormal gyrification in presymptomatic carriers showed no concomitant cortical thickness abnormality. Overall, for both presymptomatic carriers and healthy controls, gyrification and cortical thickness measures were not correlated, suggesting that gyrification captures a feature distinct from cortical thickness. Conclusions Presymptomatic c9orf72 expansion carriers show regions of abnormally low gyrification as early as their 30s, decades before expected symptom onset. Cortical gyrification represents a novel grey matter metric distinctive from grey matter thickness or volume and detects differences in presymptomatic carriers at an early age.
AB - Objective To investigate in-vivo cortical gyrification patterns measured by the local gyrification index (lGI) in presymptomatic c9orf72 expansion carriers compared with healthy controls, and investigate relationships between lGI and cortical thickness, an established morphometric measure of neurodegeneration. Methods We assessed cortical gyrification and thickness patterns in a cohort of 15 presymptomatic c9orf72 expansion carriers (age 43.7 ± 10.2 years, 9 females) compared with 67 (age 42.4 ± 12.4 years, 36 females) age and sex matched healthy controls using the dedicated Freesurfer pipeline. Results Compared with controls, presymptomatic carriers showed significantly lower lGI in left frontal and right parieto-occipital regions. Interestingly, those areas with abnormal gyrification in presymptomatic carriers showed no concomitant cortical thickness abnormality. Overall, for both presymptomatic carriers and healthy controls, gyrification and cortical thickness measures were not correlated, suggesting that gyrification captures a feature distinct from cortical thickness. Conclusions Presymptomatic c9orf72 expansion carriers show regions of abnormally low gyrification as early as their 30s, decades before expected symptom onset. Cortical gyrification represents a novel grey matter metric distinctive from grey matter thickness or volume and detects differences in presymptomatic carriers at an early age.
UR - http://www.scopus.com/inward/record.url?scp=85065571307&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065571307&partnerID=8YFLogxK
U2 - 10.1136/jnnp-2018-320265
DO - 10.1136/jnnp-2018-320265
M3 - Article
C2 - 31079065
AN - SCOPUS:85065571307
SN - 0022-3050
VL - 90
SP - 1005
EP - 1010
JO - Journal of Neurology, Neurosurgery and Psychiatry
JF - Journal of Neurology, Neurosurgery and Psychiatry
IS - 9
ER -